The clinical and molecular findings in an infant with mild manifestations of cystic fibrosis, who is homozygous for the G542X mutation, and her heterozygous nephew, who is severely affected, are described.
G542X mutation (Kerem et al, personal communication). The 2566insAT mutation was not present in our Belgian population sample. In our CF patients, the G542X mutation, in which the glycine (GGA) at amino acid position 542 in exon 11 is mutated to a stop codon (TGA), accounted for 7-3% of the CF chromosomes, being probably the second most frequent CF mutation in this population sample.
Here we describe the clinical and molecular findings in a child who is only mildly affected although homozygous for the mutation, and a child who is severely affected and heterozygous for the G542X mutation and a new mutation in exon 9 (G458V). hybridised with 32p labelled oligonucleotide probes: for the G542 codon (G542X: 5'-ACC TTC TCA AAG AAC T-3'; control: 5'ACC TTC TCC AAG AAC T-3') and for the G458 codon (G458V: 5'-GTT GCT GTA TCC ACT G-3'; control: 5'-GTT GCT GGA TCC ACT G-3').
The membranes were washed in stringent conditions (10 mins at 42°C in 6xSSC, 0 1% SDS; 2x30 mins at 450C in 2 x SSC for the control and G542X, 10 mins at 42°C in 6xSSC, 0 1% SDS; 2x30 mins at 56°C in 2 x SSC for the control of codon G458, 10 mins at 42°C in 6xSSC, 0-1% SDS; 2x30 mins at 52°C in 2xSSC for G458V) and autoradiographed for three hours at -700C.
Sequencing of the fragment containing exon 9 was done with the T7 sequencingiM kit (Pharmacia) according to the following modified protocol. The amplified fragments were purified with GeneClean (BiolOl) and were mixed with 15 ng of an internal end labelled primer (5'-CAT GGA CAC CAA ATT AAG TTC-3'). The fragments were denatured for three minutes at 100°C and cooled on ice. Annealing buffer, labelling mix, dATP, and T7 DNA polymerase were added together, mixed, and the total reaction mixture was immediately split into four tubes containing the dideoxymixes (short). The sequencing reactions were kept for five minutes at room temperature, then for C 11.1 11.2 C H.1 11.2 C H1.1 11.2 C H.1 11.2 tive minutes at 37°C and stop solution was added. The sequencing reaction products were then separated on a 6% acrylamide/8 mol/l urea gel. The gel was fixed in 10% acetic acid/10% methanol solution, dried, and exposed.
Dot blot analysis (fig 1) showed that the CF girl (II.2) was homozygous and her cousin (11.1) heterozygous for the G542X mutation. Direct sequencing of an amplified fragment, containing exon 9, of patient II.1 detected a new mutation (fig 2) , resulting in a substitution of a conserved glycine (GGA) for a valine (GTA) at amino acid position 458 (G458V). This was confirmed by dot blot analysis (fig 1) . This mutation segregates with the haplotype 2 1 1 1 (XV2c, CS7, KM19, D9). This amino acid substitution is most likely a disease mutation rather than a polymorphism because glycine is a very conserved amino acid in the nucleotide binding fold of this region and this substitution was not detected in 45 normal chromosomes, 20 of them with the same haplotype 2 1 1 1 (XV2c, CS7, KM19, D9). This mutation has been found in one out of 31 CF chromosomes, which carry a so far unknown mutation. Three other CF chromosomes with this haplotype did not carry this mutation and therefore at least one other mutation might be associated with this haplotype. This mutation has not been found in 21 AF508 chromsomes, one A1507 chromosome (CF genetic analysis consortium), or in two G542X chromosomes.
The G542X mutation segregates with the haplotype 1 2 2 2 (XV2c, CS7, KM19, D9) and was found in 10 out of 41 non-AF508, non-AI507 CF chromosomes. Since 68-1% of all CF chromosomes carry the AF508 deletion in our population sample, the G542X mutation accounts for 7-3% (10 out of 138 CF chromosomes) and the G458V mutation accounts for less than 1% (one out of 138 CF chromosomes) of all the CF chromosomes in this sample.
Based on the quite mild clinical picture, one would have expected that the CF girl carried a mutation in a non-essential part of the gene. The G542X mutation, however, creates a stop codon at amino acid 542. Therefore, only the first 541 codons, out 
